This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lappas, M. Articles by Rice, G. E. Search for Related Content PubMed PubMed Citation Articles by Lappas, M. Articles by Rice, G. E.

Regulation of Phospholipase Isozymes by Nuclear Factor-B in Human Gestational Tissues in Vitro

Department of Obstetrics and Gynaecology, The University of Melbourne and Mercy Perinatal Research Centre, Mercy Hospital for Women, East Melbourne, Victoria, Australia 3002

Address all correspondence and requests for reprints to: Martha Lappas, Department of Obstetrics and Gynaecology, University of Melbourne, Mercy Hospital for Women, 126 Clarendon Street, East Melbourne, 3002 Victoria, Australia. E-mail: mlappas{at}unimelb.edu.au.

Phospholipid-derived mediators are implicated in the initiation and progression of human labor and delivery, particularly in relation to infection-induced preterm labor. We previously demonstrated that, in human intrauterine tissues, lipopolysaccharide (LPS)-stimulated nuclear factor-B (NF-B) DNA binding activity, and subsequent cytokine release can be suppressed by sulfasalazine (SASP) concentrations greater than 5 mM. The aim of this study was to elucidate the effect the SASP on secretory type II phospholipase A₂ (PLA₂), cytosolic PLA₂ (cPLA₂), cyclooxygenase (COX) isozymes, and subsequent prostaglandin F₂ (PGF₂) production in human gestational tissues. Human placenta, amnion, and choriodecidua (n = 4–9 separate placentas) were incubated in the presence of SASP (0.1, 1, 5, and/or 10 mM) under either basal or LPS (10 µg/ml) conditions. After 6 h incubation, the tissues were collected and assayed for type II PLA₂ by ELISA and cPLA₂, COX-1, and COX-2 content by Western blotting. The incubation medium was collected and assayed for type II PLA₂ and 13,14-dihydro-15-keto PGF₂ release by ELISA and PGF₂ by RIA. Treatment of placenta, amnion, and choriodecidua with SASP concentrations greater than 5 mM significantly inhibited basal and/or LPS-stimulated type II PLA₂ content and release, 13,14-dihydro-15-keto PGF₂ release, and cPLA₂ protein content (ANOVA, P < 0.05); however, no effect of SASP was observed on basal or LPS-stimulated COX-1 or COX-2 protein. Although no effect of SASP was observed on basal and LPS-stimulated PGF₂ release from placenta and amnion, it significantly increased both basal and LPS-stimulated PGF₂ release from choriodecidua. In addition, SASP concentrations of 5 mM or greater significantly suppressed NF-B DNA binding activity. These data are consistent with the hypothesis that NF-B regulates the expression and release of phospholipase isozymes.

This work was supported by the Medical Research Foundation for Women and Babies and National Health and Medical Research Council Grant 114106. M.L. received a Postdoctoral Research Fellowship from the Elizabeth and Vernon Puzey Foundation.

Abbreviations: AP-1, Activator protein-1; COX, cyclooxygenase; cPLA₂, cytosolic PLA₂; IB, inhibitory B; LDH, lactate dehydrogenase; LPS, lipopolysaccharide; NF-B, nuclear factor-B; PGDH, prostaglandin dehydrogenase; PGF₂, prostaglandin F₂; PLA₂, phospholipase A₂; SASP, sulfasalazine.

This article has been cited by other articles:

				M. I. Patel, J. Singh, M. Niknami, C. Kurek, M. Yao, S. Lu, F. Maclean, N. J.C. King, M. H. Gelb, K. F. Scott, et al. Cytosolic Phospholipase A2-{alpha}: A Potential Therapeutic Target for Prostate Cancer Clin. Cancer Res., December 15, 2008; 14(24): 8070 - 8079. [Abstract] [Full Text] [PDF]

				M. Lappas, M. Permezel, and G. E Rice Advanced glycation endproducts mediate pro-inflammatory actions in human gestational tissues via nuclear factor-{kappa}B and extracellular signal-regulated kinase 1/2 J. Endocrinol., May 1, 2007; 193(2): 269 - 277. [Abstract] [Full Text] [PDF]

				W. Li, E. Unlugedik, A. D. Bocking, and J. R.G. Challis The Role of Prostaglandins in the Mechanism of Lipopolysaccharide-Induced proMMP9 Secretion from Human Placenta and Fetal Membrane Cells Biol Reprod, April 1, 2007; 76(4): 654 - 659. [Abstract] [Full Text] [PDF]

				D. B. Zaragoza, R. R. Wilson, B. F. Mitchell, and D. M. Olson The Interleukin 1beta-Induced Expression of Human Prostaglandin F2alpha Receptor Messenger RNA in Human Myometrial-Derived ULTR Cells Requires the Transcription Factor, NFkappaB Biol Reprod, November 1, 2006; 75(5): 697 - 704. [Abstract] [Full Text] [PDF]

				S.R. Sooranna, P.L. Grigsby, N. Engineer, Z. Liang, K. Sun, L. Myatt, and M.R. Johnson Myometrial prostaglandin E2 synthetic enzyme mRNA expression: spatial and temporal variations with pregnancy and labour Mol. Hum. Reprod., October 1, 2006; 12(10): 625 - 631. [Abstract] [Full Text] [PDF]

				T. M Lindstrom and P. R Bennett The role of nuclear factor kappa B in human labour Reproduction, November 1, 2005; 130(5): 569 - 581. [Abstract] [Full Text] [PDF]

				N. R. Chapman, I. Smyrnias, D. O. C. Anumba, G. N. Europe-Finner, and S. C. Robson Expression of the GTP-Binding Protein (G{alpha}s) Is Repressed by the Nuclear Factor {kappa}B RelA Subunit in Human Myometrium Endocrinology, November 1, 2005; 146(11): 4994 - 5002. [Abstract] [Full Text] [PDF]